Skip to main content

Exciting New Data Presented on NSCLC at AACR 2021

Conference Correspondent  - AACR & ASCO 2021 - Midyear Review
David Spigel, MD
Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Dr David Spigel discusses key presentations on immunotherapy and targeted therapy in the neoadjuvant and adjuvant settings in NSCLC.
Related Items
2021 Midyear Review: Non–Small-Cell Lung Cancer
Conference Correspondent  published on June 20, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Clinical Outcomes for Plasma-Based Genomic Profiling versus Tissue Testing in Advanced NSCLC (NILE)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Pooled Analyses of Immune-Related Adverse Events and Efficacy from IMpower130, IMpower132, and IMpower150
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Anti–PD-L1 Therapy in Combination with Chemotherapy versus Immunotherapy Alone in First-Line NSCLC with PD-L1 Score 1% to 49%
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Comparison of Aumolertinib and Gefitinib in First-Line Treatment of EGFR-Mutated NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Racial Disparities in Biomarker Testing and Clinical Trial Enrollment in NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Rucaparib in High Genomic Loss of Heterozygosity and/or BRCA1/2-Mutated NSCLC (Lung-MAP Sub-Study, S1900A)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Capmatinib in MET Exon 14–Mutated Advanced NSCLC (GEOMETRY Mono-1 Study)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review